Is Renal Denervation Back?

In a proof-of-concept trial, the procedure reduced blood pressure in low-risk patients who were not taking oral antihypertensives.

Renal sympathetic hyperactivity is a contributor to hypertension, and renal denervation (RDN) by percutaneous ablation was for a time considered a very promising novel treatment approach. Early, nonrandomized studies showed dramatic reductions of blood pressure with RDN in patients with resistant hypertension, but later studies with sham controls did not confirm the initial results (NEJM JW Gen Med May 1 2014 and N Engl J Med 2014; 370:1393).

Now, investigators have performed a manufacturer-funded, proof-of-concept, sham-controlled, multicenter, randomized study in 80 patients with mild-to-moderate hypertension who were not on blood pressure medication (ClinicalTrials.gov NCT02439749). At 3 months, ambulatory systolic blood pressure had drop…

Reviewing Author

Pascal Meier, MD

Disclosures

Editorial BoardsOpen Heart

Leadership Positions in Professional SocietiesEuropean Society of Cardiology (Communication Committee); European Association of Percutaneous Cardiovascular Interventions (Chair, Web & Communication Committee)

Pascal Meier, MD

Disclosures

Editorial BoardsOpen Heart

Is Renal Denervation Back?

Topics

Reviewing Author